Serum homocysteine, folate and risk of stroke: Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study by Virtanen, J. K. et al.
Original Scientific Paper
Serum homocysteine, folate and risk of stroke: Kuopio
Ischaemic Heart Disease Risk Factor (KIHD) Study
Jyrki K. Virtanena, Sari Voutilainena, Pertti Happonenb, Georg Alfthanc,
Jari Kaikkonend, Jaakko Mursua, Tiina H. Rissanena,b, George A. Kaplane,
Maarit J. Korhonenb, Juhani Siveniusf and Jukka T. Salonena,d
aResearch Institute of Public Health, University of Kuopio, Kuopio, bDepartment of Public Health and
General Practice, University of Kuopio, Kuopio, cBiomarker Laboratory, National Public Health Institute,
Helsinki, dOy Jurilab Ltd, Kuopio, Finland, eUniversity of Michigan, School of Public Health, Department of
Epidemiology, Michigan, USA and fUniversity Hospital of Kuopio, Brain Research and Rehabilitation
Center Neuron, Kuopio, Finland.
Received 18 October 2004 Revised 10 January 2005 Accepted 4 February 2005
Background Homocysteine and folate have been suggested to have opposite effects on the risk of stroke, although the
results are controversial.
Design and methods The purpose of this study was to assess the effects of serum total homocysteine (tHcy) and serum
folate levels on the risk of stroke in a prospective cohort study. The subjects were 1015 men aged 46–64 years and free of
prior stroke, examined in 1991–1993 in the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study.
Results At baseline the mean serum tHcy concentration was 10.9 lmol/l (SD 3.4). During an average follow-up time of 9.6
years, 49 men experienced a stroke, of which 34 were ischaemic. In Cox proportional hazards models, men in the highest
tHcy third had a risk factor-adjusted hazard rate ratio (RR) of 2.77 [95% confidence interval (CI): 1.23–6.24] for any stroke
and 2.61 (95% CI: 1.02–6.71) for ischaemic stroke, compared with men in the lowest third. The mean baseline serum folate
concentration was 10.4 nmol/l (SD 4.1). Men in the highest third of serum folate ( > 11.2 nmol/l) had an adjusted RR for any
stroke of 0.35 (95% CI: 0.14–0.87) and for ischaemic stroke of 0.40 (95% CI: 0.15–1.09), compared with men in the lowest
third.
Conclusion Elevated serum tHcy is associated with increased risk of all strokes and ischaemic strokes in middle-aged
eastern Finnish men free of prior stroke. On the other hand, high serum folate concentration may protect against
stroke. Eur J Cardiovasc Prev Rehabil 12:369–375 c 2005 The European Society of Cardiology
European Journal of Cardiovascular Prevention and Rehabilitation 2005, 12:369–375
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Introduction
Stroke is one of the leading causes of morbidity and
mortality in the developed countries. One of the
proposed risk factors for stroke is serum homocysteine
(Hcy), an intermediate amino acid produced during the
metabolism of methionine. Four meta-analyses have
suggested that serum total homocysteine (tHcy) con-
centration is a risk factor for cardiovascular diseases
(CVD), including stroke [1–4], one suggesting that the
association is causal [1].
Folate plays an important role as a methyl donor in the re-
methylation of Hcy back to methionine. This has raised
interest in the role of folate in the prevention of CVD.
Indeed, low serum or dietary folate is associated with
increased serum tHcy concentration [5], and on the other
hand, folate supplementation is an effective way to
decrease serum tHcy [6]. Furthermore, there are several
findings of an inverse relationship between dietary or
serum folate and risk of stroke [7–9].
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In this prospective cohort study we investigated the
effects of serum tHcy and folate levels on the risk of all
strokes and on ischaemic strokes in middle-aged men
from eastern Finland. We also wanted to study whether




The Kuopio Ischaemic Heart Disease Risk Factor
(KIHD) Study is an ongoing prospective population-
based cohort study designed to investigate risk factors
for CVD, atherosclerosis and related outcomes in
middle-aged men from eastern Finland [10], the popula-
tion with one of the highest recorded rates of coronary
heart disease (CHD). A total of 2682 participants (82.9%
of those eligible), aged 42, 48, 54, or 60 years, were
enrolled in the study between 1984 and 1989. The
baseline examinations for the present analysis were
carried out during 1991–1993 at the 4-year re-examina-
tions of the KIHD study. Out of the total of 1229 men
eligible for the study, 52 had died, had had a severe
illness, or had migrated from the region, and 139 could
not be contacted or refused to participate. Thus, 1038
men were examined in 1991–1993, of which data on
serum tHcy concentration was available for 1027 men.
Men with a history of stroke (n = 12) were excluded,
leaving 1015 men for the final analyses. Data on income
was available for 996 men and on total physical activity for
1010 men. The population mean for these two variables
was used to replace the missing values in statistical
analyses.
Determination of serum tHcy concentration
The serum tHcy concentration was analyzed by high-
performance liquid chromatography [11] with modifica-
tions described by Schwab et al. [12] in 2001 at the
National Public Health Institute, Helsinki, Finland. The
results represent total serum homocysteine, which is
referred as serum tHcy. The coefficient of variation (CV)
between batches (n = 30) for two-pooled serum samples
were 4.3 and 5.4% at levels 11.2 and 7.4 mmol/l,
respectively. The mean bias in a quality-control program
was 2.2% [12].
Determination of serum folate concentration
Serum folate concentration was measured by radio-
immunoassay (Quantaphase II; Bio-Rad, Hercules,
California, USA). Folate measurements were carried out
in 1998 in serum samples collected during 1991–1993 and
kept frozen at – 801C. The between-batch CV of quality
control serum (Lyphochek Immunoassay Plus Control
levels 1, 2, 3, Bio Rad Laboratories, ECS
Division, Anaheim, California, USA) at levels 5.5, 13.4
and 23.6 nmol/l were 6.4, 6.7 and 6.7%, respectively
(n = 16).
Other measurements
Assessment of medical history, smoking and alcohol
consumption using both questionnaires and interviews,
and assessment of blood pressure were carried out as
described previously [13]. The collection of blood
specimens and measurement of serum lipids and
lipoproteins and plasma lycopene and beta-carotene have
been described in detail elsewhere [13–15]. Physical
activity in leisure time was assessed from a 12-month
history, modified from the Minnesota leisure time
physical activity questionnaire; the intensity of physical
activity was expressed in metabolic equivalents of oxygen
consumption [16]. The 12-month history gives a more
accurate estimate of the past level of physical activity
than shorter-term measurements [17]. Body mass index
(BMI) was computed as the ratio of weight in kilograms
to the square of height in metres.
Ascertainment of follow-up events
Incident strokes between 1984 and 1992 were ascer-
tained through the FINMONICA stroke register [18].
Information on stroke incidence between 1993 and 31
December 2002 was obtained by computerized linkage to
the Finnish national hospital discharge registry and death
certificate registry. Diagnostic information was collected
from hospitals and classified by a neurologist (J.S.) using
diagnostic criteria identical to the FINMONICA criteria.
The sources of information on stroke were from hospital
documents, death certificates, autopsy reports, and
medico-legal reports. The diagnosis of stroke was based
on the sudden onset of clinical signs or focal or global
disturbance of cerebral function lasting > 24 h (except in
the case of sudden death or when interrupted by surgical
intervention) with no apparent cause other than a
vascular origin. Each suspected stroke (ICD-9 codes
430–439 and ICD-10 codes I60–I68 and G45–G46) was
classified as: (1) definite stroke; (2) no stroke; or (3) an
unclassifiable event. The data from the FINMONICA
stroke register were annually rechecked with the data
obtained from the computerized national hospital dis-
charge and death registers. Definite strokes and un-
classifiable events were included in the group of any
stroke. Each definite stroke was classified as: (1) an
ischaemic stroke (ICD-9 codes 433–434 or ICD-10 code
I63); or (2) a haemorrhagic stroke (ICD-9 codes 430–431
or ICD-10 codes I60–I61). If the subject had multiple
strokes during follow-up, the first event was considered
the end point.
Statistical methods
The data are expressed as means ± SD. Means were
compared with analysis of variance (ANOVA). Categorical
variables were compared with the chi-square test.
Correlations were estimated with Pearson correlation
coefficients (r). Cox proportional hazards models were
used to analyze the associations between serum tHcy or
folate and incidence of stroke. Risk factor adjusted hazard
370 European Journal of Cardiovascular Prevention and Rehabilitation 2005, Vol 12 No 4
Copyright © European Society of Cardiology. Unauthorized reproduction of this article is prohibited.
rate ratios (RR) were estimated as the antilogarithms of
coefficients from multivariable models. Systolic blood
pressure, smoking, diabetes, body mass index (BMI),
serum total and low-density lipoprotein (LDL) choles-
terol, alcohol intake, history of ischaemic heart disease,
income, and total physical activity were considered as
confounders. These factors were eliminated from the full
model if their joint removal did not result in a change of
the tHcy RR of 10% or more. Age and examination year
were forced in the models. Confidence intervals (CI)
were estimated on the basis of the assumption of
asymptotic normality of the estimates. All tests of
significance were two-sided. Data were analyzed using
SPSS 11.0 for Windows (SPSS Inc., Chicago, Illinois,
USA).
Results
At baseline the mean serum tHcy concentration was
10.9 mmol/l (SD 3.4, min–max 2.8–51.2 mmol/l). The men
in the highest serum tHcy third were older, had lower
serum folate and high-density lipoprotein (HDL) con-
centrations and higher triglyceride concentrations, higher
systolic blood pressure and higher prevalence of sympto-
matic ischaemic heart disease or history of ischaemic
heart disease compared to the lowest third (Table 1).
The mean serum folate concentration was 10.4 nmol/l
(SD 4.1, min–max 2.3–40.5 nmol/l). The men in the
highest serum folate third were younger and had higher
total and HDL cholesterol and triglyceride concentra-
tions and lower serum tHcy concentrations. They also
had higher systolic and diastolic blood pressure, BMI and
alcohol intake and were more physically active. In
addition, they smoked less and had a higher prevalence
of diabetes than men in the lowest third (Table 2).
During a mean follow-up time of 9.6 years (SD 2.2) 49
men experienced a stroke, of which 34 were ischaemic.
The subjects were divided into thirds based on the serum
tHcy concentration. The age and examination year
adjusted RRs for any stroke in thirds of + Hcy were 1,
2.16 (95% CI: 0.94–4.96) and 2.77 (95% CI: 1.23–6.24),
the P for linear trend across the thirds was 0.014. The age
and examination year adjusted RRs for ischaemic stroke
in thirds of + Hcy were 1, 1.71 (95% CI: 0.63–4.64) and
2.61 (95% CI: 1.02–6.71), the P for linear trend being
0.039. Additional adjustment for stroke risk factors
(systolic blood pressure, smoking, diabetes, BMI, serum
total and LDL cholesterol, alcohol intake, history of
ischaemic heart disease, income, and total physical
activity) or serum folate did not change the results.
Figure 1a presents the age and examination year adjusted
stroke survival curves for men in each serum tHcy third.
The age and examination year adjusted RRs for any stroke
in the thirds of serum folate were 1, 1.04 (95% CI: 0.57–
1.90) and 0.43 (95% CI: 0.18–1.05), the P for linear trend
being 0.200. The respective RRs for ischaemic strokes
were 1, 0.81 (95% CI: 0.38–1.72) and 0.49 (95% CI: 0.18–
1.31), the P for linear trend being 0.361. After additional
adjustment for alcohol intake and diabetes the RRs for
any stroke were 1, 1.00 (95% CI 0.55–1.83) and 0.35 (95%
CI: 0.14–0.87), with a P for linear trend being 0.046. The
RRs for ischaemic stroke were 1, 0.79 (95% CI 0.37–1.68)
and 0.40 (95% CI: 0.15–1.09), with a P for linear trend
being 0.117, after additional adjustment for serum LDL
cholesterol and diabetes. Further adjustment for other
Table 1 Baseline characteristics of the 1015 study participants in thirds of the serum total homocysteine concentration
Serum total homocysteine (mmol/l)
< 9.6 9.6–11.4 Z11.4 P
Number of subjects 340 337 338
Number of all stroke events [n (% of subjects)] 8 (2.4) 18 (5.3) 23 (6.8) 0.022
Serum tHcy (mmol/l) 8.4 (1.0) 10.4 (0.5) 14.0 (4.1)
Serum folate (nmol/l) 11.4 (4.2) 10.3 (3.9) 9.3 (4.0) < 0.001
Age (years) 55.1 (6.5) 56.0 (6.7) 57.4 (6.6) < 0.001
Serum total cholesterol (mmol/l) 5.52 (0.93) 5.63 (0.92) 5.43 (0.94) 0.020
Serum LDL cholesterol (mmol/l) 3.92 (0.82) 4.02 (0.85) 3.85 (0.84) 0.030
Serum HDL cholesterol (mmol/l) 1.12 (0.28) 1.12 (0.29) 1.06 (0.29) 0.006
Serum triglycerides (mmol/l) 1.55 (0.93) 1.61 (1.13) 1.71 (1.05) 0.131
Blood pressure (mmHg)
Systolic 134 (16) 136 (16) 137 (17) 0.030
Diastolic 88 (10) 89 (10) 90 (10) 0.213
Body mass index (kg/m2) 27.4 (3.8) 27.6 (3.5) 27.5 (3.6) 0.614
Alcohol (g/week) 81.6 (116.6) 69.1 (88.1) 86.8 (153.6) 0.155
Total physical activity (MET h/day)* 47.9 (11.3) 47.3 (10.5) 46.8 (11.5) 0.446
Income (euros)w 14440 (8030) 15940 (10260) 14470 (9510) 0.061
Smoker (%) 30.3 28.2 25.7 0.418
Diabetes (%) 6.2 8.9 5.3 0.156
Symptomatic IHD or IHD history (%) 18.2 18.7 26.0 0.020
All values are means ( ± SD). SD, standard deviation; tHcy, total homocysteine; LDL, low-density lipoprotein; HDL, high-density lipoprotein; MET, metabolic equivalent;
IHD, ischaemic heart disease. *Data available for 1010 men. wData available for 996 men.
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risk factors (systolic blood pressure, smoking, diabetes,
BMI, serum total and LDL cholesterol, alcohol intake,
history of ischaemic heart disease, income, and total
physical activity) and serum tHcy did not change the
results. Neither did adjustment for plasma lycopene and
beta-carotene. Figure 1b presents the age, examination
year, alcohol intake and diabetes adjusted stroke survival
curves for men in each serum folate third.
The RRs according to serum tHcy and folate medians
were also determined. The risks of any stroke and
ischaemic stroke were increased in the group of men with
both elevated serum tHcy and low serum folate
concentrations compared with the group of men with
low serum tHcy and high serum folate (Table 3). No
significant increase in risk was observed in men with
elevated serum tHcy when serum folate was above
median (group 3). The correlation between serum tHcy
and serum folate was – 0.15 (P < 0.001).
Discussion
The main finding of this prospective cohort study was
that high serum tHcy concentration may increase and
high serum folate concentration may decrease the risk of
any stroke and ischaemic stroke in middle-aged men from
eastern Finland who were free of previous stroke at
baseline.
There are some limitations in our study. First, the number
of events was relatively low, which also prevented us from
studying the risks of haemorrhagic strokes separately.
Secondly, serum folate was used instead of dietary folate
and although serum and dietary folate are well correlated,
serum folate may not be a good indicator of long-term
dietary intake. Unfortunately dietary intakes were not
assessed at the baseline for this study and neither was red
cell folate, which is considered to be a marker of long-
term folate status [19]. Finally, since folate is found
mainly in foodstuffs of plant origin, other nutrients may
also contribute to the benefit. However, plasma levels of
lycopene and beta-carotene, also markers of a healthy
diet, did not attenuate the beneficial effect of folate.
There are several meta-analyses concerning the associa-
tion between high blood tHcy concentration and
increased risk of stroke [1–4]. In one meta-analysis the
association has been suggested to be causal; the authors
conclude that lowering tHcy concentrations by 3 mmol/l
from current levels would reduce the risk of stroke by 19–
24% [1]. Another meta-analysis suggested a 19% reduc-
tion in stroke risk with the same 3 mmol/l lowering of
tHcy concentration [2]. This reduction in tHcy would be
achievable by increasing folate intake [20,21]. In two
previous Finnish nested case–control studies the results
have been inconsistent [22,23]. A recent study of 201
cerebral infarction cases and 201 controls of the cohort of
13 840 male smokers free of CVD of the Alpha-Tocopherol
and Beta-Carotene (ATBC) Cancer Prevention study
found a graded increase in the odds ratio (OR) of cerebral
infarction per quarter increase in tHcy concentration
[22]. In these 50- to 69-year-old men the adjusted OR in
the highest quarter compared with lowest quarter was 2.1
(95% CI: 1.1–3.9). In contrast, in the earlier study of 42
male and 32 female stroke cases between 40 and 64 years
of age and without prior CVD of a total study population
of 7048, no association was found between tHcy and risk
of stroke in either gender [23]. The authors of the ATBC
study consider this discrepancy to be due to the relatively
low mean and range of tHcy in the other Finnish study
Table 2 Baseline characteristics of the 1015 study participants in thirds of the serum folate concentration
Serum folate (nmol/l)
< 8.2 8.2–11.2 Z 11.2 P
Number of subjects 346 334 335
Number of all stroke events [n (% of subjects)] 19 (5.5) 19 (5.7) 11 (3.3) 0.272
Serum folate (nmol/l) 6.7 (1.2) 9.7 (0.9) 14.8 (3.9)
Serum tHcy (mmol/l) 11.8 (4.1) 10.6 (2.6) 10.4 (2.9) < 0.001
Age (years) 56.9 (6.8) 56.2 (6.3) 55.4 (6.7) 0.009
Serum total cholesterol (mmol/l) 5.44 (0.91) 5.56 (0.95) 5.58 (0.94) 0.081
Serum LDL cholesterol (mmol/l) 3.91 (0.87) 3.98 (0.84) 3.91 (0.81) 0.424
Serum HDL cholesterol (mmol/l) 1.07 (0.29) 1.11 (0.27) 1.12 (0.31) 0.023
Serum triglycerides (mmol/l) 1.58 (1.09) 1.52 (0.88) 1.76 (1.12) 0.010
Blood pressure (mmHg)
Systolic 134 (16) 135 (17) 137 (17) 0.037
Diastolic 88 (10) 88 (10) 91 (10) < 0.001
Body mass index (kg/m2) 27.2 (3.5) 27.2 (3.5) 28.1 (3.7) 0.001
Alcohol (g/week) 58.7 (86.0) 66.2 (99.7) 113.2 (162.1) < 0.001
Total physical activity (MET h/day)* 46.0 (10.5) 47.4 (10.9) 48.7 (11.8) 0.006
Income (euros)w 14130 (8720) 16130 (10330) 14610 (8760) 0.015
Smoker (%) 33.8 25.5 24.8 0.014
Diabetes (%) 3.2 6.3 11.0 < 0.001
Symptomatic IHD or IHD history (%) 24.9 19.2 18.8 0.093
All values are means ( ± SD). SD, standard deviation; tHcy, total homocysteine; LDL, low-density lipoprotein; HDL, high-density lipoprotein; MET, metabolic equivalent;
IHD, ischemic heart disease. *Data available for 1010 men. wData available for 996 men.
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compared to their study or interaction between smoking
and tHcy [22]. Differences in the mean tHcy levels,
although small, could also explain part of the incon-
sistency with our study and the earlier study [23].
In our previous study in this same study population tHcy
was not associated with acute coronary events [24,25].
This may be due to different mechanism(s) by which
Hcy induces stroke compared to acute coronary disease.
Also, the smaller diameter of cerebral arterioles may make
them more susceptible to oxidative damage, which has
been proposed as one mechanism by which Hcy induces
its negative effects, in addition to induction of endo-
thelial injury [26]. However, the mechanisms are not
completely understood.
High serum folate concentration, on the other hand, was
associated with lower risk of stroke, which is in line with
previous studies that have studied either serum or dietary
folate [7–9]. Furthermore, if serum folate levels were
above the median, tHcy did not increase the risk of
stroke. Neither did addition of tHcy as a covariate in the
folate models. This could suggest that folate may be
beneficial independently of tHcy concentration, which
has also been reported before [27,28]. As is the case with
Hcy, the mechanisms behind folate’s beneficial effects
are still unclear. There is, however, some evidence that
folic acid or its metabolite 5-methyltetrahydrofolate may
directly improve endothelial function, possibly by rever-
sing endothelial dysfunction and reducing plaque size/
growth [29]. In our previous studies serum folate has also
been associated with greatly reduced incidence of acute
coronary events [25,30], suggesting a systemic protective
effect of folate against CVD. On the other hand, a recent
randomized controlled trial failed to find an effect on
recurrent stroke, CHD events or death after high-dose
vitamin therapy (folic acid, B6, B12) compared with low-
dose vitamin therapy during the 2 years of follow-up in
patients with non-disabling cerebral infarction [31]. The
mean reduction of tHcy in the high-dose group was
2 mmol/l greater than in the low-dose group. They
however found a persistent and graded association
between baseline tHcy and outcomes. As the authors
commented, the follow-up time may have been too short
to find an effect. Also, the coincided folic acid fortifica-
tion of the US grain supply with the initiation of the trial
probably had reduced the prevalence of low folate and
high tHcy levels, persons who might have been most
likely to benefit [31]. Thus, trials using different
populations and a longer follow-up time are needed to
clarify whether tHcy is an independent risk factor or only
a marker for CVD and whether folate has a beneficial
impact independent of blood tHcy concentration, as has
been suggested [27,28]. Several such trials are currently
underway [32]. Unfortunately the two other large trials in
North America designed to investigate the effects of folic
acid and other B vitamins on cardiovascular outcomes are
also affected by the folic acid fortification, which may
reduce the statistical power to detect any effects of
vitamin supplementation [33]. In the Finnish study
populations the range of serum folate is large, thus
increasing the power to find associations between folate
and risk of events. Furthermore, there are no folate
fortification programmes in Finland.
In conclusion, this study suggests that: (1) elevated
serum tHcy concentration may increase the risk of stroke;
and (2) high serum folate concentration may protect
against stroke in middle-aged Finnish men without prior
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Age and examination year adjusted stroke survival curves for thirds of
serum total homocysteine (tHcy) (a) and age, examination year, alcohol
intake and diabetes adjusted survival curves for thirds of serum
folate (b).
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whether supplementation with folic acid is beneficial
against CVD.
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